Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

DrugCendR begins CEND1-001 trial for pancreatic cancer

CEND-1 is a peptide that has the potential to treat pancreatic cancer. Credit: Sanford Burnham Prebys Medical Discovery Institute.

Go Top